Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG017 in Postmenopausal Women With Stress Urinary Incontinence
CTR20213214Phase 2Completed
- Sponsor
- Ningbo Xijian Medical Science & Technology
- Start
- Dec 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in stress urinary incontinence (SUI) comparing EG017 with Placebo (2 arms). Primary endpoint: Proportion reduction in 1-hour pad test leakage after 12 weeks vs baseline. Started Dec 2021; status: completed.
02
Drugs
EG-017
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on CTR20213214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213214.